Finance

Lists
NPNKF:OTCMKTS
Nippon Shinyaku Co Ltd
$23.50
0.00%
(0.00) 1D
Aug 17, 12:05:44 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NPNKF...
Mkt. cap
237.94B
Avg. vol.
40.00
Volume
0.00
52-wk high
$38.01
52-wk low
$21.00
Beta
-3.25
Shares outstanding
70.25M
No. of employees
2K
Mkt. cap
237.94B
Avg. vol.
40.00
Volume
0.00
52-wk high
$38.01
52-wk low
$21.00
Beta
-3.25
Shares outstanding
70.25M
No. of employees
2K
Profile
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that markets prescription drugs and functional foods. Nippon Shinyaku has developed treatments such as viltolarsen for Duchenne muscular dystrophy. Wikipedia
About Nippon Shinyaku Co Ltd
CEO-
Employees2.31K
FoundedOct 1, 1919
Headquarters-
SectorPharmaceutical industry
Websitenippon-shinyaku.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
40.10B
47.49B
43.64B
49.07B
Cost of goods sold
12.68B
16.68B
15.45B
17.73B
Cost of revenue
12.68B
16.68B
15.45B
17.73B
Research and development expenses
8.45B
8.40B
13.68B
9.20B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.36B
11.35B
10.89B
11.08B
Operating expense
17.92B
18.06B
27.55B
19.03B
Total operating expenses
30.60B
34.73B
43.00B
36.75B
Operating income
9.50B
12.75B
639.00M
12.31B
Other non operating income
1.00M
-2.00M
323.00M
-1.00M
EBT including unusual items
9.53B
13.20B
3.24B
12.96B
EBT excluding unusual items
9.53B
13.20B
3.35B
12.96B
Income tax expense
2.02B
3.11B
-642.00M
2.85B
Effective tax rate
21.19%
23.57%
-19.83%
22.00%
Other operating expenses
-888.00M
-1.68B
2.01B
-1.24B
Net income
7.50B
10.08B
3.88B
10.11B
Net profit margin
18.72%
21.23%
8.88%
20.60%
Earnings per share
-
-
-
-
Interest and investment income
82.00M
464.00M
119.00M
689.00M
Interest expense
-55.00M
-19.00M
-
-41.00M
Net interest expenses
27.00M
445.00M
119.00M
648.00M
Depreciation and amortization charges
-
-
974.00M
-
EBITDA
11.14B
14.41B
2.38B
14.09B
Gain or loss from assets sale
19.00M
56.00M
56.00M
-473.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps